Literature DB >> 16105506

Visualizing drug efficacy in vivo.

Zhang Weisheng1, Chen Min, David B West, Anthony F Purchio.   

Abstract

Many enzymes are therapeutic targets for drug discovery, whereas other enzymes are important for understanding drug metabolism and pharmacokinetics during compound testing in animals. Testing of drug efficacy and metabolism in an animal model requires the measurement of disease endpoints as well as assays of enzyme activity in specific tissues at selected time points during treatment. This requires the removal of tissue and biochemical assays. Techniques to noninvasively assess drug effects on enzyme activity using imaging technology would facilitate understanding of drug efficacy, pharmacokinetics, and drug metabolism. Using a commercially available cytochrome P-450 3A substrate whose oxidized product is a luciferase substrate, we show for the first time that cytochrome P-450 enzyme activity can be measured in vivo in real time by bioluminescent imaging. This imaging approach could be applicable to study drug effects on therapeutic target enzymes, as well as drug metabolism enzymes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16105506

Source DB:  PubMed          Journal:  Mol Imaging        ISSN: 1535-3508            Impact factor:   4.488


  3 in total

Review 1.  Non-invasive molecular imaging for preclinical cancer therapeutic development.

Authors:  A C O'Farrell; S D Shnyder; G Marston; P L Coletta; J H Gill
Journal:  Br J Pharmacol       Date:  2013-06       Impact factor: 8.739

2.  Novel photoactivatable substrates for Renilla luciferase imaging in vitro and in vivo.

Authors:  Chaochao Zhang; Lin Cheng; Gaopan Dong; Guangxi Han; Xingye Yang; Chunchao Tang; Xiang Li; Yubin Zhou; Lupei Du; Minyong Li
Journal:  Org Biomol Chem       Date:  2018-07-04       Impact factor: 3.876

3.  Novel caged luciferin derivatives can prolong bioluminescence imaging in vitro and in vivo.

Authors:  Chaochao Zhang; Mingliang Yuan; Guangxi Han; Yuqi Gao; Chunchao Tang; Xiang Li; Lupei Du; Minyong Li
Journal:  RSC Adv       Date:  2018-05-30       Impact factor: 4.036

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.